Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Rizzo

Showing results (71-80 of 381) with videos related to

Pageof 39
Sort By:
Future Oncology (London, England)|January 29, 2021
DNA damage response alterations in gastric cancer: knocking down a new wallAngela Dalia Ricci, Alessandro Rizzo, Giovanni Brandi
The Oncologist|February 4, 2021
In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)"Angela Dalia Ricci, Alessandro Rizzo, Giovanni Brandi
Liver Cancer|May 31, 2022
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
The Oncologist|August 22, 2022
Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular CarcinomaAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Future Oncology (London, England)|January 29, 2021
Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapyAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
The Lancet. Gastroenterology & Hepatology|June 1, 2024
Immunotherapy in biliary tract cancer: are we finally on the right path?Angela Dalia Ricci, Alessandro Rizzo, Claudio Lotesoriere
Expert Opinion on Investigational Drugs|March 1, 2021
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancerAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications|February 21, 2021
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinomaAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Journal of Personalized Medicine|December 29, 2022
Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An UpdateAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
The Oncologist|July 28, 2020
Regarding "HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer"Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Pageof 39

Showing results (71-80 of 381) with videos related to

Sort By:
Pageof 39
Future Oncology (London, England)|January 29, 2021
DNA damage response alterations in gastric cancer: knocking down a new wallAngela Dalia Ricci, Alessandro Rizzo, Giovanni Brandi
The Oncologist|February 4, 2021
In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)"Angela Dalia Ricci, Alessandro Rizzo, Giovanni Brandi
Liver Cancer|May 31, 2022
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
The Oncologist|August 22, 2022
Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular CarcinomaAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Future Oncology (London, England)|January 29, 2021
Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapyAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
The Lancet. Gastroenterology & Hepatology|June 1, 2024
Immunotherapy in biliary tract cancer: are we finally on the right path?Angela Dalia Ricci, Alessandro Rizzo, Claudio Lotesoriere
Expert Opinion on Investigational Drugs|March 1, 2021
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancerAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications|February 21, 2021
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinomaAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Journal of Personalized Medicine|December 29, 2022
Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An UpdateAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
The Oncologist|July 28, 2020
Regarding "HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer"Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Pageof 39